Table I.

Patient characteristics at time of nab-paclitaxel administration (n=9).

Patient	Age (years)	Gender	PS (ECOG)	Disease extent	No. of previous chemotherapy regimens	No. of nab-paclitaxel cycles	Sensitivity to first-line chemotherapy	Previous paclitaxel treatment
1	69	Male	1	ED	9	4	Sensitive	Yes
2	73	Male	0	LD	6	2	Sensitive	Yes
3	65	Female	2	ED	2	2	Refractory	No
4	68	Male	1	ED	5	4	Sensitive	No
5	76	Male	0	LD	5	4	Sensitive	Yes
6	56	Female	1	ED	2	2	Sensitive	No
7	67	Male	0	ED	2	1	Refractory	No
8	64	Male	0	ED	2	1	Refractory	No
9	60	Female	2	ED	3	1	Refractory	No

Nab, nanoparticle albumin-bound; PS, performance status; ECOG, Eastern Cooperative Oncology Group; LD, limited disease; ED, extensive disease.